The third study, by Sorensen found that glycopeptideresistant and streptogramin-resistant strains of Efaecium, isolated from chicken parts obtained at a grocery store and from pigs after slaughter, were able to colonize transiently (up to 14 days) the intestinal tract of healthy volunteers. They attributed the emergence of glycopeptideresistant strains to the earlier widespread use of avoparcin in animal feed in Europe, noting that in 1997 its use was banned by countries in the European Union.
Gorbach, in an accompanying editorial, commented that the use of antimicrobials in food animals selects for resistant strains and enhances their persistence in the environment. Another concern is the horizontal spread of the resistance genes from bacteria in food animals to commensal strains in the intestinal microflora of humans.
On the basis of discussions by an expert committee of the Alliance for the Prudent Use of Antibiotics, several recommendations were made, including (1) antimicrobials should be used only when indicated in individual infected animals for a targeted pathogen and prescribed by a veterinarian; (2) the use of certain drugs that have important uses in humans, such as fluoroquinolones and third-generation cephalosporins, should be prohibited in animals; and (3) the subtherapeutic use of these agents to promote growth and feeding efficiency should be banned-a move that would decrease the burden of antimicrobial resistance in the envi- 
Effect of Vancomycin and Cephalosporins on VRE in ICUs
Patient-specific risk factors for acquisition of vancomycin-resistant enterococci (VRE) among hospitalized patients are becoming well-defined. However, few studies have reported data on the institutional risk factors, including rates of antimicrobial use that predict rates of VRE. Identifying modifiable institutional factors can advance quality-improvement efforts to minimize hospital-acquired infections with VRE. Fridkin and colleagues from the CDC's Division of Healthcare Quality Promotion, the Intensive Care Antimicrobial Resistance Epidemiology (ICARE) Project, and the National Nosocomial Infections Surveillance System hospitals conducted a study to determine the independent importance of any association between antimicrobial use and risk factors for nosocomial infection on rates of VRE in ICUs. The study was a prospective ecological study in 126 adult ICUs from 60 US hospitals from January 1996 through July 1999. Included were all patients admitted to participating ICUs. Monthly use of antimicrobial agents (defined daily doses/1,000 patient-days), nosocomial infection rates, and susceptibilities of all tested enterococci isolated from clinical cultures were determined.
Prevalence of VRE (median, 10%; range, 0% to 59%) varied by type of ICU, as well as by teaching status and hospital size. Prevalence of VRE was strongly associated with VRE prevalence among inpatient non-ICU areas and outpatient areas in the hospital, ventilator-days per 1,000 patient-days, and rate of parenteral vancomycin use. In a weighted linearregression model controlling for type of ICU and rates of VRE among non-ICU inpatient areas, rates of vancomycin use (P<.001) and third-generation cephalosporin use (P=.02) were independently associated with VRE prevalence.
